News

Ultromics collaborates with Mayo Clinic to optimize the impact of AI tools on care pathways

Ultromics, a health-tech company which applies AI to echocardiography, to earlier detect and better diagnose heart disease, has entered a know-how and clinical research agreement with Mayo Clinic. Underpinned …

New Strain code is first Echo technology to get Medicare reimbursement in over a decade

As of January 1 2020, cardiologists in the United States can now report and bill for myocardial strain imaging using the new Category 1 CPT code +93356. The policy …

Mayo Clinic collaborates with Ultromics to rapidly assess patients diagnosed with COVID-19

Collaboration between Ultromics and Mayo Clinic aims to quantify cardiac involvement in COVID-19 and help triage high-risk patients with myocardial injury A joint UK-US research team is applying a …

Ultromics CE mark’s AI system EchoGo Pro

The AI technology can be used for the first time to accurately and instantly predict heart disease risk through non-invasive, ultrasound analysis. This is the primary imaging test to …

Cardiac disease in pregnancy: how AI technology can help midwives with frontline detection

The theme of this year’s World Health Day (April 7th) is to recognise the work of nurses and midwives and remind world leaders of the critical role they play …

Ultromics achieves ISO 27001 certification

  Ultromics has received ISO 27001 certification. The standard recognises our commitment to data security and ensures, for patients, clinicians and healthcare providers, that personal healthcare information and other …

Ultromics receives FDA clearance

  Ultromics receives FDA clearance for its AI-powered decision support system, EchoGo Core.   AI automates cardiac analysis helping earlier detection of cardiovascular disease, enabling clinicians to improve patient …

Ultromics secures £10 million investment to bring AI heart diagnostics to hospitals

Ultromics, the UK start-up behind breakthrough artificial intelligence (AI) technology for the diagnosis of coronary heart disease, has raised £10 million in Series-A investment. The funding was led by …

Ultromics secures additional £1m investment from Woodford Investment Management

Ultromics is excited to announce our latest investor, Woodford Investment Management, who have added £1m to our recently closed £10m Series A round. Woodford Investment Management joins a group …

Artificial intelligence to diagnose heart disease

*Pending FDA 510(k) clearance, not available for sale in the United States, not CE-marked

**CAUTION–Investigational device. Limited by Federal (or United States) law to investigational use